Journal
GASTROENTEROLOGY
Volume 142, Issue 6, Pages 1373-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2012.02.011
Keywords
Rapid Fibrosers; Slow Fibrosers; Protease Inhibitors; Direct Acting Antivirals; Waiting List
Categories
Funding
- Roche
- MSD
- Novartis
- Instituto de Salud Carlos III [PI080239]
- European Regional Development Fund (ERDF)
- Hospital Clinic (Ajut a la Recerca Josp Font)
- Fundacion BBVA
Ask authors/readers for more resources
Liver transplantation is the only alternative for patients with end-stage liver disease. Viral hepatitis B and C are among the most common causes of cirrhosis and hepatocellular carcinoma and a frequent indication for liver transplantation. Hepatitis B virus immunoglobulin and nucleot(s)ide analogues have facilitated the management of patients with hepatitis B who have received liver transplants and resulted in excellent long-term outcomes. On the contrary, recurrence of hepatitis C is the main cause of graft loss in most transplant programs. Current therapeutic approaches are far from optimal, because sustained virologic responses are only achieved in one-third of treated patients, and adverse effects are common and severe. However, the rapid development of direct-acting antivirals against hepatitis C virus will change the management of this disease and in a few years prevent graft infection with this virus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available